Cell Source, Inc. balance sheet CLCS

Annual Quarterly

As of Mar 31, 2025, Cell Source, Inc. had total assets of $292,446 and total liabilities of $20.4 million. Total assets were up 254.1% from a year earlier. Stockholders' equity was negative, at -$20.1 million, because liabilities exceed assets. It held $1,240 in cash and investments against $314,985 of total debt, net debt of $313,745.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024	Q2 FY2024 Jun 30, 2024	Q1 FY2024 Mar 31, 2024	Q4 FY2023 Dec 31, 2023	Q3 FY2023 Sep 30, 2023	Q2 FY2023 Jun 30, 2023
Assets
Cash	0 +5291.3%	0 +236.1%	0 +790.5%	0	0	0	0	—
Cash and investments	0 +5291.3%	0 +236.1%	0 +790.5%	0	0	0	0	—
Total assets	0 +254.1%	0 +46.8%	0 +6.6%	0 +18.6%	0 -64.5%	0 -52.4%	0 -31.1%	0 +711.7%
Liabilities and equity
Accounts payable	2 +2.5%	2 +28.7%	2 +28.8%	2 +88.8%	2 +58.6%	1 +115.6%	2 +134.5%	1 +142.9%
Total liabilities	20 +21.3%	19 +19.1%	19 +18.0%	18 +15.9%	17 +16.5%	16 +21.2%	16 +32.2%	15 +41.6%
Stockholders' equity	-20 -20.2%	-19 -18.7%	-19 -18.2%	-17 -15.9%	-17 -17.8%	-16 -23.6%	-16 -34.1%	-15 -38.8%
Debt
Lease liabilities	0 +1329.6%	0 +649.4%	0 +142.2%	0 +6.9%	0	0 +50.5%	0	0
Total debt	0 +1329.6%	0 +649.4%	0 +142.2%	0 +6.9%	0	0 +50.5%	0	0
Net cash	-0 -1325.5%	-0 -1112.1%	-0 -129.1%	-0	-0	-0	-0	—
Ratios
Return on assets	-1,613.66%	-1,575.09%	-1,976.59%	-1,198.84%	-5,939.11%	-2,726.44%	-2,258.27%	-1,524.24%
Book value per share	-0.45	-0.41	-0.44	-0.41	-0.41	-0.39	-0.42	-0.39

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CLCS (OTC)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: New York, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1569340
Former names: TICKET TO SEE, INC. (until Jun 26, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.